Why the study?
Does hepatic intra-arterial chemotherapy with Adriamycin improve clinical remission in a patient with metastatic leiomyosarcoma of the liver failing systemic therapy?
Does hepatic intra-arterial chemotherapy with Adriamycin improve clinical remission in a patient with metastatic leiomyosarcoma of the liver failing systemic therapy?
Hepatic intra-arterial adriamycin may provide lasting clinical remission in metastatic leiomyosarcoma of the liver failing systemic therapy.
Answers are grounded in this paper and cite their sources.
May support hepatic intra-arterial adriamycin after systemic failure; hypothesis-generating and requires prospective validation before practice change.
We report a case of extensive leiomyosarcoma of the liver that failed on systemic Adriamycin. Hepatic intra-arterial chemotherapy with Adriamycin has resulted in a lasting clinical remission. This report illustrates the importance of the dose-response curve of drug to tumor in regional chemotherapy as with Adriamycin used in sarcoma, and the need to further explore such therapy in moderately chemosensitive tumors that are surgically unresectable for anatomic reasons.
No takes yet. Share an insight, caveat, or question.
Khansur et al. (1987) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: